Epizyme, Inc.
(NASDAQ GS: EPZM)
Rigrodsky Law, P.A. is investigating Epizyme, Inc. (“Epizyme”) regarding possible breaches of fiduciary duties and other violations of law related to Epizyme’s agreement to be acquired by Ipsen S.A. Under the terms of the agreement, Epizyme’s shareholders will receive $1.45 in cash and one contingent value right (CVR) of $1.00 for each share of Epizyme common stock they own.